The cobas 6800 and cobas 8800 Systems : A New Era of Automation in Molecular Diagnostics

The cobas 6800 and cobas 8800 Systems : A New Era of Automation in Molecular Diagnostics

8th Dec 2025

The cobas 6800 and cobas 8800 Systems : A New Era of Automation in Molecular Diagnostics

(Scientific blog inspired by Cobb et al., 2017 )

this blog is intended for educational and scientific purposes only. All trademarks and product names mentioned, are the property of their respective owners and are used solely for descriptive purposes.

Molecular diagnostics has become the beating heart of modern laboratory medicine. From infectious disease detection to blood safety and personalized medicine, PCR-based testing now influences 70–80% of all clinical decisions. Yet for decades, molecular labs were slowed by manual workflows, complex protocols, and limited scalability.

The arrival of the cobas® 6800 and cobas® 8800 Systems marks a turning point a true shift toward total laboratory automation (TLA). These systems integrate sample preparation, PCR amplification, detection, quality control, and data reporting into a fully automated workflow, dramatically reducing hands-on time while maximizing throughput and reliability.

Below, we explore how these systems work, why they matter, and how they redefine diagnostic efficiency. 

Read the Full Article

                                                                  


1. From Manual PCR to High-Throughput Automation

PCR revolutionized diagnostics after its discovery in 1983, but early workflows still depended on manual pipetting, multiple rooms, and hours of technician involvement. Problems like contamination, inconsistent amplification, and slow turnaround were common.

Over time, innovations such as:
✔ thermostable polymerases
✔ hot-start PCR
✔ uracil-N-glycosylase contamination control
✔ real-time fluorescence detection

…allowed PCR to become faster and more accurate but not fully automated.

The cobas® 6800/8800 Systems represent the culmination of these innovations, delivering a platform where sample in → result out happens with minimal human intervention.


2. What Makes the cobas® 6800/8800 Systems Different?

Universal sample preparation & reagents

Both systems use a single standardized nucleic acid extraction method, capable of isolating both DNA and RNA from diverse sample types.
This “universal” approach means:

  • same reagents for most assays

  • same thermocycling profile

  • only primers/probes change from test to test

This drastically accelerates assay development, especially for emerging pathogens.


 High Throughput, Low Hands-On Time

According to the technical data:

  • cobas® 6800: up to 384 samples / 8 hours

  • cobas® 8800: up to 960 samples / 8 hours

  • Hands-on time: 30–60 minutes per shift

  • First results in under 3.5 hours

The system automatically manages batching, sample loading, reagent usage, and control verification.


 True Mix-Batching

The platform can run up to 3 different assays simultaneously in one batch of 96 samples something that older systems struggled to manage due to different thermocycling conditions.

This helps labs:

  • avoid sample pre-sorting

  • run urgent tests immediately

  • increase productivity without adding staff


Strong Quality & Traceability Controls

Built-in features include:

  • RFID-tracked reagent kits

  • full sample traceability

  • automatic contamination control (UNG step)

  • internal control (IC/QS) for every sample

This reduces errors and meets regulatory requirements more easily.


3. Pre-Analytical & Post-Analytical Integration

Automation doesn’t stop at PCR.
The platform integrates with cobas® pre-analytics modules:

  • cobas p 312 (sorting + decapping)

  • cobas p 512 / p 612 (sorting, decapping, aliquoting, centrifugation)

  • Sample Source Module for conveyor-based lab automation

This allows molecular diagnostics to be physically connected to clinical chemistry, hematology, and serology workflows a big step toward hospital-level TLA.


4. The Utility Channel: A Game Changer for LDT Development

One of the most innovative features is the Utility Channel (UC).

It allows labs to develop and validate Laboratory Developed Tests (LDTs) using the same:

  • universal reagents

  • plates

  • pipette tips

  • processing workflow

Labs simply add custom primers/probes.

This hybrid model offers:

  • higher quality reagents

  • simpler validations

  • faster development cycles

  • reduced manual steps

Ideal for emerging disease detection (Ebola, Zika, H5N1, etc.).


5. Applications: From Infectious Diseases to Blood Safety

Approved assays (depending on region) include:

  • HIV-1, HBV, HCV viral load

  • multiplex donor screening (MPX: HIV, HBV, HCV)

  • CMV monitoring

  • HEV, WNV donor screening

  • Zika virus screening (IND approval in the U.S.)

Performance data from the PDF shows:

  • HIV-1 LOD ~13 cp/mL

  • HBV LOD ~6.6 IU/mL

  • HCV LOD ~12 IU/mL

This level of sensitivity is essential for detecting low viral loads in both diagnostic and screening settings.


6. Why This Technology Matters

For clinicians

  • faster test results

  • greater diagnostic confidence

  • improved ability to monitor treatment response

For patients

  • earlier diagnosis

  • more precise treatment

  • reduced waiting times

For laboratories

  • minimal hands-on work

  • expanded testing capacity

  • fewer errors & contamination events

For public health

  • rapid response to emerging pathogens

  • safer blood supplies

  • scalable testing during outbreaks

The system proved its value during Zika and would play a critical role in any future epidemic.


7. Future Outlook

The authors predict (correctly) that the next five years would bring:

  • deeper integration with hospital IT

  • consolidation of lab workspaces

  • automated pre-analytics + molecular testing pipelines

  • faster development of assays for emerging diseases


Conclusion

The cobas® 6800/8800 Systems represent a major leap forward in molecular diagnostics.
By combining universal reagents, standardized thermocycling, high throughput, and automation from sample to result, they allow labs to deliver faster, more reliable, and more scalable PCR testing than ever before.

For any facility looking to modernize its diagnostic capabilities, especially in infectious diseases and donor screening, these systems mark the beginning of a new era one where automation, precision, and speed define the future of molecular testing.